Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Melphalan PHP in Uveal Melanoma
NCT07364474Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of melphalan in Uveal melanoma (UM) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Intratumoral CXCL13+ CD8+ T-cell infiltration. Started Jan 2026; status: recruiting.
02
Drugs
melphalan
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT07364474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364474.